Drug Trial Radar · NCT06709014
A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
861
Actual
Start
Feb 4, 2025
Primary completion
Dec 2027
Study completion Jun 2028
Sponsor
- Lead sponsor
- Annovis Bio Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Prevail Infoworks; ProPharma Group
- First posted
- Nov 29, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 55 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if buntanetap/Posiphen works to treat early Alzheimer's disease in adults aged 55-85. It will also learn about the safety of buntanetap/Posiphen. The main questions it aims to answer are: * Does buntanetap/Posiphen improve cognition as measured by ADAS-Cog13? * Does buntanetap/Posiphen improve function as measured by ADCS-iADL? * What medical issues do participants have, if any, when taking buntanetap/Posiphen? Researchers will compare buntanetap/Posiphen to a placebo (a look-alike substance that contains no drug) to see if buntanetap/Posiphen works to treat early Alzheimer's disease. Participants will: * Take buntanetap/Posiphen or a placebo every day for 18 months * Visit the clinic periodically for checkups, tests, and questionnaires (screening visits, enrollment, month 1, month 3, month 6, month 9, month 12, month 15, month 18), including a volumetric MRI at month 6 and month 18 * Complete pre- and post-clinic visit phone calls
Conditions
- Early Alzheimers Disease
Interventions
buntanetap/posiphenDrug
30mg capsule by mouth once daily for 18 months
PlaceboDrug
Placebo capsule by mouth once daily for 18 months
Primary outcomes
What the sponsor says the trial is designed to measure.
- Alzheimer's Disease Assessment Scale-Cognitive Subscale 13 (ADAS-Cog13)Time frame: From screening to 6-month readout, to end of treatment at 18 months.
- Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living Scale (ADCS-iADL)Time frame: From screening to 6-month readout, to end of treatment at 18 months.
Locations
78 sites in 1 country. Site status is shown where the registry gives one.
MD First Research
Chandler, Arizona
Xenoscience
Phoenix, Arizona
Clinical Endpoints
Scottsdale, Arizona
Advanced Research Center
Anaheim, California
Hope Clinical Research
Canoga Park, California
Sun Valley Research
Imperial, California
Mary S. Easton Center for Alzheimer's Research and Care, UCLA
Los Angeles, California
UC Davis Alzheimer's Disease Research Center
Sacramento, California
The Neuron Clinic
San Marcos, California
Mountain Neurological Center
Basalt, Colorado
CenExel Rocky Mountain
Englewood, Colorado
Research Center for Clinical Trials
Norwalk, Connecticut
Visionary Investigators Network
Aventura, Florida
SFM Clinical Research
Boca Raton, Florida
K2 Medical Research
Clermont, Florida
K2 Medical Research Daytona
Daytona Beach, Florida
Neuropsychiatric Research Center
Fort Myers, Florida
Velocity Clinical
Hallandale, Florida
Jacksonville Center for Clinical Research
Jacksonville, Florida
K2 Medical Research
Lady Lake, Florida
Headlands Research JEM
Lake Worth, Florida
Accel Research Sites Lakeland (Alcanza)
Lakeland, Florida
K2 Medical Research
Maitland, Florida
ClinCloud Clinical Research
Melbourne, Florida
Flourish Research/Merritt Island Medical Research
Merritt Island, Florida
Miami Jewish Health
Miami, Florida
Aqualane Clinical Research
Naples, Florida
Suncoast Clinical Research
New Port Richey, Florida
Conquest Research
Orlando, Florida
Axiom Brain Health, LLC
Tampa, Florida
Conquest Research
Winter Park, Florida
Accel Neurosciences
Decatur, Georgia
CARE (Center for Advanced Research & Education)
Gainesville, Georgia
Hawaii Pacific Neuroscience
Honolulu, Hawaii
Re:Cognition Chicago
Chicago, Illinois
Rush University Medical Center
Chicago, Illinois
Charter Research Chicago
Chicago, Illinois
Great Lakes Clinical Trials/Flourish Research
Chicago, Illinois
Southern Illinois University
Springfield, Illinois
JWM Research
Indianaopolis, Indiana
Showing 40 of 78 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.